PT2849730T - Nova composição de alfentanilo para o tratamento de dor aguda - Google Patents

Nova composição de alfentanilo para o tratamento de dor aguda

Info

Publication number
PT2849730T
PT2849730T PT137273140T PT13727314T PT2849730T PT 2849730 T PT2849730 T PT 2849730T PT 137273140 T PT137273140 T PT 137273140T PT 13727314 T PT13727314 T PT 13727314T PT 2849730 T PT2849730 T PT 2849730T
Authority
PT
Portugal
Prior art keywords
treatment
new
acute pain
alfentanil
composition
Prior art date
Application number
PT137273140T
Other languages
English (en)
Portuguese (pt)
Inventor
Pettersson Anders
Schwan Emil
Johansson Barbro
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48577134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2849730(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1207701.2A external-priority patent/GB201207701D0/en
Priority claimed from GBGB1221130.6A external-priority patent/GB201221130D0/en
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of PT2849730T publication Critical patent/PT2849730T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT137273140T 2012-05-02 2013-05-01 Nova composição de alfentanilo para o tratamento de dor aguda PT2849730T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1207701.2A GB201207701D0 (en) 2012-05-02 2012-05-02 New pharmaceutical composition
GBGB1221130.6A GB201221130D0 (en) 2012-11-23 2012-11-23 New pharmaceutical composition

Publications (1)

Publication Number Publication Date
PT2849730T true PT2849730T (pt) 2017-02-15

Family

ID=48577134

Family Applications (2)

Application Number Title Priority Date Filing Date
PT137273140T PT2849730T (pt) 2012-05-02 2013-05-01 Nova composição de alfentanilo para o tratamento de dor aguda
PT16197166T PT3150199T (pt) 2012-05-02 2013-05-01 Nova composição de alfentanilo para o tratamento de dor aguda

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT16197166T PT3150199T (pt) 2012-05-02 2013-05-01 Nova composição de alfentanilo para o tratamento de dor aguda

Country Status (33)

Country Link
US (4) US8815911B2 (enExample)
EP (2) EP3150199B1 (enExample)
JP (1) JP6275696B2 (enExample)
KR (1) KR20150005695A (enExample)
CN (1) CN104427978B (enExample)
AU (1) AU2013255640B2 (enExample)
BR (1) BR112014027213A8 (enExample)
CA (1) CA2871805A1 (enExample)
CL (1) CL2014002979A1 (enExample)
CO (1) CO7170181A2 (enExample)
CY (2) CY1118570T1 (enExample)
DK (2) DK3150199T3 (enExample)
EA (1) EA028110B1 (enExample)
ES (2) ES2614757T3 (enExample)
HR (2) HRP20161634T1 (enExample)
HU (1) HUE031792T2 (enExample)
IL (1) IL235272B (enExample)
IN (1) IN2014MN02156A (enExample)
LT (2) LT3150199T (enExample)
ME (1) ME02644B (enExample)
MX (1) MX360665B (enExample)
NZ (1) NZ701428A (enExample)
PE (1) PE20142444A1 (enExample)
PH (1) PH12014502407B1 (enExample)
PL (2) PL2849730T3 (enExample)
PT (2) PT2849730T (enExample)
RS (2) RS55489B1 (enExample)
SG (1) SG11201407081PA (enExample)
SI (2) SI2849730T1 (enExample)
SM (3) SMT201800585T1 (enExample)
TR (1) TR201815935T4 (enExample)
WO (1) WO2013164620A1 (enExample)
ZA (1) ZA201407559B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2915525B1 (en) 2011-09-19 2021-08-11 Orexo AB Sublingual abuse-resistant tablets comprising buprenorphine and naloxone
WO2013164620A1 (en) * 2012-05-02 2013-11-07 Orexo Ab New alfentanil composition for the treatment of acute pain
US10766925B2 (en) * 2016-04-11 2020-09-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Opioid receptor modulators
JP7023054B2 (ja) * 2017-04-05 2022-02-21 東和薬品株式会社 レベチラセタム含有医薬組成物及びその製造方法
CN115047109B (zh) * 2022-06-17 2024-05-31 三明海关综合技术服务中心 一种检测食品中芬太尼类新精神活性物质的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
DE19758564A1 (de) 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
GB9904911D0 (en) 1999-03-03 1999-04-28 Scherer Ltd R P Pharmaceutical compositions
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20020160043A1 (en) 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
ES2270335T7 (es) 2003-01-31 2012-03-16 Orexo Ab Composicion farmaceuta de efecto.
MXPA05008918A (es) 2003-02-24 2006-02-17 Pharmaceutical Productions Inc Sistema de administracion transmucosal de farmacos.
US20050042281A1 (en) 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
WO2005065317A2 (en) 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
BRPI0418213A (pt) 2003-12-31 2007-04-27 Cima Labs Inc forma de dosagem, e, método para tratar dor em um paciente em necessidade do mesmo
US20070036853A1 (en) 2003-12-31 2007-02-15 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
PT1708686E (pt) 2003-12-31 2011-04-20 Cima Labs Inc Forma de dosagem de fentanil oral efervescente geralmente linear e métodos de administração
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
CA2599386A1 (en) 2005-03-28 2006-10-05 Orexo Ab New pharmaceutical compositions useful in the treatment of pain
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
US20070104763A1 (en) * 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) * 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8535714B2 (en) * 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252328B2 (en) 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US20070286900A1 (en) 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
US20100233257A1 (en) 2006-06-09 2010-09-16 Ethypharm Low dose sublingual tablets of opioid analgesics and preparation process
KR101329496B1 (ko) * 2006-07-21 2013-11-13 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 향상된 흡수를 갖는 경점막 전달 장치
US8470361B2 (en) 2006-12-04 2013-06-25 Orexo Ab Non-abusable pharmaceutical composition comprising opioids
EP1964564A1 (en) 2007-04-19 2008-09-03 LAB International SRL Breakthrough Pain Management
CN101820838B (zh) 2007-08-07 2013-06-05 阿塞尔Rx制药有限公司 采用口腔经粘膜剂型的用于程序镇静和镇痛的组合物和方法
US20090263476A1 (en) 2008-04-16 2009-10-22 Jobdevairakkam Christopher N Composition of Rapid Disintegrating Direct Compression Buccal Tablet
US8343978B2 (en) 2008-08-04 2013-01-01 Adds Pharmaceuticals Llc Fast onset orodispersable tablets
WO2010027770A1 (en) 2008-09-04 2010-03-11 Mallinckrodt Inc. Crystalline forms of sufentanil citrate
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
MX2011012043A (es) 2009-05-13 2012-03-29 Protein Delivery Solutions Llc Sistema farmaceutico para suministro transmembrana.
WO2010141505A1 (en) 2009-06-01 2010-12-09 Protect Pharmaceutical Corporation Abuse-resistant delivery systems
JP2009280611A (ja) * 2009-08-26 2009-12-03 Kyukyu Yakuhin Kogyo Kk 口腔内粘膜フィルム剤
US20110091544A1 (en) 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
WO2011057199A1 (en) 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
US20110150989A1 (en) 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
WO2013164620A1 (en) * 2012-05-02 2013-11-07 Orexo Ab New alfentanil composition for the treatment of acute pain

Also Published As

Publication number Publication date
EP2849730B1 (en) 2016-11-09
JP6275696B2 (ja) 2018-02-14
SMT201700086T1 (it) 2017-03-08
HUE031792T2 (en) 2017-07-28
ES2694644T3 (es) 2018-12-26
US8815911B2 (en) 2014-08-26
EA028110B1 (ru) 2017-10-31
CL2014002979A1 (es) 2014-12-05
IL235272B (en) 2018-10-31
CY1120820T1 (el) 2019-12-11
CN104427978B (zh) 2017-03-01
PL2849730T3 (pl) 2017-05-31
SMT201800585T1 (it) 2019-01-11
JP2015515974A (ja) 2015-06-04
RS55489B1 (sr) 2017-04-28
TR201815935T4 (tr) 2018-11-21
EP2849730A1 (en) 2015-03-25
CN104427978A (zh) 2015-03-18
US9782396B2 (en) 2017-10-10
BR112014027213A2 (pt) 2017-06-27
SG11201407081PA (en) 2014-11-27
CY1118570T1 (el) 2017-07-12
BR112014027213A8 (pt) 2018-01-16
KR20150005695A (ko) 2015-01-14
ZA201407559B (en) 2016-05-25
US20170071927A1 (en) 2017-03-16
HRP20181761T1 (hr) 2018-12-28
NZ701428A (en) 2016-10-28
ME02644B (me) 2017-06-20
PE20142444A1 (es) 2015-01-09
DK3150199T3 (en) 2018-11-12
PH12014502407A1 (en) 2015-01-12
SI3150199T1 (sl) 2018-12-31
IN2014MN02156A (enExample) 2015-08-28
EP3150199B1 (en) 2018-08-08
PT3150199T (pt) 2018-11-21
US20140005223A1 (en) 2014-01-02
EA201401200A1 (ru) 2015-02-27
ES2614757T3 (es) 2017-06-01
US9345698B2 (en) 2016-05-24
LT2849730T (lt) 2016-12-27
PH12014502407B1 (en) 2015-01-12
WO2013164620A1 (en) 2013-11-07
US20150133501A1 (en) 2015-05-14
DK2849730T3 (en) 2017-02-13
EP3150199A1 (en) 2017-04-05
HRP20161634T1 (hr) 2017-01-13
SMT201700086B (it) 2017-03-08
CA2871805A1 (en) 2013-11-07
MX360665B (es) 2018-11-13
HK1203399A1 (en) 2015-10-30
AU2013255640B2 (en) 2017-06-15
PL3150199T3 (pl) 2019-03-29
MX2014013176A (es) 2015-01-19
US20180214437A1 (en) 2018-08-02
AU2013255640A1 (en) 2014-11-20
RS57951B1 (sr) 2019-01-31
SI2849730T1 (sl) 2017-02-28
CO7170181A2 (es) 2015-01-28
LT3150199T (lt) 2018-11-12

Similar Documents

Publication Publication Date Title
IL266582A (en) Preparations and methods for the treatment of hemoglobin diseases
EP2847152A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF METABOLIC SYNDROME
EP2675469A4 (en) COMPOSITIONS, DEVICES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER
ZA201408055B (en) Compositions and methods for the treatment of local pain
IL238027A0 (en) 2-phenyl-5-heterocyclyl-tetrahydro-h2-pyran-3-amine compounds for use in the treatment of diabetes and related disorders
ZA201408056B (en) Compositions and methods for the treatment of mucositis
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
SMT201800604T1 (it) Composti per il trattamento di obesita' e metodi di uso degli stessi
HRP20181761T1 (hr) Novi pripravak alfentanila za liječenje akutne boli
ZA201405161B (en) Hair treatment composition
ZA201305939B (en) Hair treatment composition
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
EP2812190A4 (en) SURFACE TREATMENT COMPOSITION
IL234616A0 (en) A herbal preparation for the treatment of metabolic diseases
ZA201408065B (en) Compositions and methods for the treatment of diabetes
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
ZA201408053B (en) Compositions and methods for the treatment of metabolic syndrome
LT2863932T (lt) Kompozicija, skirta naudoti limfedemos gydymui
HUE039044T2 (hu) Gyógyászati kompozíció sclerosis multiplex kezelésére
ZA201501109B (en) Hard surface treatment composition
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds
GB201110653D0 (en) Composition for skin treatment
GB201110659D0 (en) composition for skin treatment